The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.
“Let’s be honest. There’s not that much money in the moonshot. I just don’t think it is going to have that big an impact. More than 800 drugs are in cancer clinical trials. That’s really where we should be focused,” stated Vice Provost for Global Initiatives Ezekiel Emanuel.
“The cancer moonshot evokes a very positive time in American history,” said Risa Lavizzo-Mourey, the president of the Robert Wood Johnson Foundation. “One thing I hope the moonshot will address is the racial disparities that exist in cancer care.”
“The FDA will play a huge role in the moonshot. The investment of not just money but also breaking down barriers to sharing of information could really make a difference,” stated Robert Califf, the commissioner of the U.S. Food and Drug Administration. “If a cancer moonshot is ever going to work, this would be the time to do it.”
Read full, original post: Health experts offer their support for—and skepticism of—the cancer moonshot